ArticleScientific reports2026
Machine learning-based prognostic signature integrating mitochondrial function and programmed cell death patterns in pancreatic adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interplay between mitochondria and programmed cell deaths (PCD) is associated with tumor pathogenesis. However, the specific roles of genes related to mitochondrial function and PCD patterns in pancreatic adenocarcinoma (PAAD) remain unclear. Though integrated multi-omics and bioinformatic analyses, we identified PCD activity-associated mitochondrial function genes (PCDMGs), and constructed a robust prognostic signature containing eight PCDMGs via CoxBoost+StepCox algorithms[both] algorithms. The constructed nomogram was validated to have superior prognostic predictive efficacy. Multiple-dimensional analyses demonstrated that the prognostic signature was significantly correlated with oncogenic pathways activation, tumor microenvironment (TME) reconstruction, and genomic variants. Drug sensitivity analysis indicated the high-risk group derived more benefits from immunotherapy but less from chemotherapy and targeted therapy. A ceRNA regulatory network was also constructed to elucidate the potential molecular mechanism of PAAD, and molecular docking simulations revealed favorable binding of the target proteins to prevalent anticancer agents. Finally, qRT-PCR in 6 PAAD patients confirmed the elevated expression levels of the eight model genes in tumor tissues, corroborating the bioinformatic findings. In conclusion, the prognostic signature and nomogram can stratify PAAD patients by prognosis and drug sensitivity, thus assisting clinicians in treatment optimization and clinical decision-making .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.